Skip to content

Inspection Record

Musculoskeletal Transplant Foundation — FDA 483 Findings

US FDAInspected 2015-07-23Published 2024-01-17 13 findingsOther quality systemAseptic processing and sterility assuranceEquipment and facilityComplaint and recall handlingContamination controlDeviation, CAPA, and investigationLabeling and packaging

Inspectors Jennifer Macmillan · Sarah M. ForneyThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

The quality program has not established and maintained appropriate monitoring systems.

2Aseptic processing and sterility assurance

Environmental controls do not provide for adequate cleaning and disinfecting of rooms and equipment to ensure aseptic processing.

3Other quality system

Adverse reactions involving a communicable disease related to HCT/Ps were not investigated.

4Equipment and facility

Procedures for the cleaning of equipment were not established.

5Other quality system

The quality program has not ensured that appropriate corrective actions relating to core CGTP requirements are taken and documented.

6Other quality system

Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not followed.

7Complaint and recall handling

Complaints were not reviewed and evaluated to determine if the complaint is related to an HCTIP deviation or adverse reaction and whether a report to FDA is required.

8Complaint and recall handling

The complaint file did not contain sufficient information about each complaint for proper review and evaluation and did not c ontain sufficient information for determining whether the complaint is an iso lated event or represents a trend.

9Other quality system

Adverse reactions which involved a communicable disease related to an HCT/P made available for distribution and were fatal or life threatening, resulted in permanent impairment or damage to the body, or necessitated medical or surgical intervention, were not reported to FDA.

10Contamination control

HCT/Ps were not processed in a way that does not cause contamination or cross contamination during processing and that does not increase the risk of introduction, transmission, or spread of communicable disease.

11Deviation, CAPA, and investigation

HCTIP deviations relating to core CGTP requirements that occurred in your establishment were not reported to FDA.

12Labeling and packaging

Labeling procedures were not designed to ensure proper HCTIP identification and to prevent mix-ups.

13Other quality system

Adverse reactions were not reported to FDA using form FDA 3500A within I 5 calendar days ofi nitial receipt of information.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2024-01-17. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Musculoskeletal Transplant Foundation company profile — full historyAll US FDA findings US FDA documents, 2024 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.